Document is current
Any future updates will be listed below
-
Authors
Ben-Yehuda, Hila
Arad, Michal
Peralta Ramos, Javier María
Sharon, Efrat
Castellani, Giulia
Ferrera, Shir
Cahalon, Liora
Colaiuta, Sarah Phoebeluc
Salame, Tomer-Meir
Schwartz, Michal https://orcid.org/0000-0003-4015-7507
-
Funding
Funding for this research was provided by:
Advanced European Research Council grants (741744)
Israel Science Foundation (991/16)
ISF-Legacy Heritage Bio-medical Science Partnership (1354/15)
Thompson and Adelis foundations
Ministry of Science and Technology, Israel
- License Information
-
More Information
Article History
Received: 19 November 2020
Accepted: 26 May 2021
First Online: 25 June 2021
Declarations
:
: Not applicable.
: Not applicable.
: M.S. is an inventor of the intellectual property that forms the basis for development of PD-L1 immunotherapy for AD.
